Prothrombotic Factors and Anaesthesia in Prostate Cancer

Prothrombotic Factors , Angiogenic Growth Factor and Different Anaesthetic Techniques in Cancer Patients Undergoing Prostatectomy

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01998685

Enrollment

200

Registered

2013-12-02

Start date

2013-06-30

Completion date

2014-11-30

Last updated

2014-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostatic Cancer, Surgery

Keywords

Prostatectomy, Coagulation Factor, Balanced Anesthesia, Intravenous Anesthesia,

Brief summary

This study aims to assess if different anesthetic techniques can affect coagulant factors in patients with prostate cancer undergoing elective laparoscopic radical prostatectomy (LRP).

Detailed description

The utility of anti-thrombotic prophylaxis in cancer patients undergoing laparoscopic radical prostatectomy (LRP) is still controversial. Moreover, different anaesthetic techniques could modify coagulant factors. Thus, in this study we will be to investigate the variations of pro- and anti-coagulant and fibrinolytic factors in two established types of anaesthesia in patients with prostate cancer undergoing elective LRP.

Interventions

DRUGPropofol

DRUGremifentanyl

DRUGMidazolam

DRUGFentanyl

DRUGSevoflurane

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

MALE

Age

40 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* newly diagnosed cancer of the prostate * histological Gleason score evaluation.

Exclusion criteria

* ASA \>2 * metabolic equivalent task \< 4 * BMI\>30 * no pre-operative pharmacological thromboprophylaxis and/or anti-coagulant therapy * history of abnormal bleeding, or abnormal coagulant factors * sepsis within the last 2 weeks * previous new adjuvant treatments (chemo, hormone, and radiotherapy) * non-steroid , anti-inflammatory and statins drugs for at least 2 wks before surgery * venous or arterial thromboembolism within the last 3 months, peripheral venous disease * neurological disease with extremity paresis * chronic liver disease * pre-operative haemoglobin concentration \< 9 mg dl-1 * prolonged duration of surgery (\>3 hrs) * peri-operative blood transfusion * not adequate material for laboratory testing

Design outcomes

Primary

Measure	Time frame
Rate of rate of prothrombotic markers and Vascular Endothelial Growth Factor (VEGF) variation	24 hours

Secondary

Measure	Time frame
Free-desease survivall	2 years

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026